Skip to main content

Metabolic Syndrome

  • Chapter
  • First Online:
Metabolism of Human Diseases

Abstract

The metabolic syndrome (MetS) is a cluster of the most dangerous heart attack risk factors, and up to a quarter of the world’s adults might have MetS. In general, cardiovascular diseases (CVD) are the most common cause of death in the world. As most patients show no obvious symptoms prior to the first incident, identification of risk factors and early intervention are important. Hypercholesterolemia is a well-established strong risk factor and is a primary target for the prevention of CVD (Fig. 1, see chapter “Hyperlipidemia”). MetS has been identified as the second target. It was previously called syndrome X [1] and insulin resistance syndrome [2], as low insulin sensitivity occurs frequently in this condition (Fig. 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607

    Article  CAS  PubMed  Google Scholar 

  2. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194

    Article  CAS  PubMed  Google Scholar 

  3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  4. Vague J (1947) La différenciation sexuelle: facteur déterminant des formes de l’obesité. Presse Med 30:339–340

    Google Scholar 

  5. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54:254–260

    Article  CAS  PubMed  Google Scholar 

  6. Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514–1520

    Article  CAS  PubMed  Google Scholar 

  7. Matsuzawa Y, Fujioka S, Tokunaga K, Tarui S (1992) Classification of obesity with respect to morbidity. Proc Soc Exp Biol Med 200:197–201

    Article  CAS  PubMed  Google Scholar 

  8. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2008) Metabolic syndrome. J Atheroscler Thromb 15:1–5

    Article  PubMed  Google Scholar 

  9. Maeda N, Funahashi T, Shimomura I (2008) Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9. Nat Clin Pract Endocrinol Metab 4:627–634

    CAS  PubMed  Google Scholar 

  10. Funahashi T, Matsuzawa Y (2007) Metabolic syndrome: clinical concept and molecular basis. Ann Med 39:482–494

    Article  CAS  PubMed  Google Scholar 

  11. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91

    Article  CAS  PubMed  Google Scholar 

  12. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800–803

    Article  CAS  PubMed  Google Scholar 

  13. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29–33

    Article  CAS  PubMed  Google Scholar 

  14. Kadowaki T, Yamauchi T (2011) Adiponectin receptor signaling: a new layer to the current model. Cell Metab 13:123–124

    Article  CAS  PubMed  Google Scholar 

  15. Ouchi N, Walsh K (2012) Cardiovascular and metabolic regulation by the adiponectin/C1q/tumor necrosis factor-related protein family of proteins. Circulation 125:3066–3068

    Article  PubMed  Google Scholar 

  16. Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55:2319–2326

    Article  CAS  PubMed  Google Scholar 

  17. Kishida K, Funahashi T, Matsuzawa Y, Shimomura I (2012) Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med 44:233–241

    Article  CAS  PubMed  Google Scholar 

  18. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I (2011) Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 10:109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tohru Funahashi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Inoue, K., Maeda, N., Funahashi, T. (2014). Metabolic Syndrome. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_30

Download citation

Publish with us

Policies and ethics